Condition: Malignant Neoplasm · Sponsor: First Affiliated Hospital of Fujian Medical University
68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.
This description comes directly from the study's public registry record.
Weibing Miao, MD · +86-0591-87981618 · miaoweibing@126.com
Jie Zang, MD · +86-0591-87981619 · 15901495106@163.com
Always discuss trial participation with your own doctor first.
| Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06688305